BillionToOne vs Fulgent Genetics
BLLN and FLGT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BLLN and FLGT compare
BillionToOne is the larger company, worth 6.9 times as much as Fulgent Genetics ($4.6B against $666M).
BillionToOne grew revenue faster over the last twelve months (71.9% versus 6.8% for Fulgent Genetics).
BillionToOne keeps more of each dollar of sales as profit, with a net margin of 11.3% compared with −26.0% at Fulgent Genetics.
BillionToOne scores higher on the StockData Score (11 against 7 for Fulgent Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BLLN | FLGT |
|---|---|---|
| Size and price | ||
| Market cap | $4.6B | $666M |
| Share price | $97.50 | $24.21 |
| Change, 1 year | 8.3% | −16.8% |
| Change, 5 years | – | −75.2% |
| Beta (5Y) | 0.38 | 0.49 |
| Employees | 713 | 1,300 |
| StockData Score | ||
| Total score | 11 (better) | 7 |
| Valuation score | 0 | 3 (better) |
| Growth score | 3 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 10.5× | 2.1× (better) |
| P/B | 8.1× | 0.7× (better) |
| EV/EBITDA | 77.8× | – |
| P/FCF | 136× | – |
| FCF yield | 0.74% (better) | −15.6% |
| Fair value | – | $45.28 |
| Margin of safety | – | 46.5% |
| Growth | ||
| Revenue growth (TTM) | 71.9% (better) | 6.8% |
| Revenue growth, 5Y average | – | −5.2% |
| Profitability | ||
| Gross margin | 71.4% (better) | 35.6% |
| Operating margin | 10.2% (better) | −37.7% |
| Net margin | 11.3% (better) | −26.0% |
| FCF margin | 7.8% (better) | −32.0% |
| Return on equity | 30.2% (better) | −8.0% |
| Return on invested capital | – | −10.9% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 (better) |
| Interest coverage | 1655× (better) | −1019.0× |
| Current ratio | 11.25 (better) | 6.34 |
| Altman Z-score | 15.56 (better) | 5.25 |
| Piotroski F-score | 8 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 9.6% |
| Shareholder yield | 0.00% | 9.6% (better) |
| Ownership | ||
| Held by institutions | 32.4% | 57.0% |
| Held by insiders | 55.7% | 39.5% |
| Insider net buying, 12 months | −$58.5M | −$286K (better) |
| Short interest, % of float | 14.2% | 12.1% |
Go deeper
- BLLN stock overview
- BLLN income statement
- BLLN valuation and score
- FLGT stock overview
- FLGT income statement
- FLGT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.